Report topline data from the Phase 3 study of lirentelimab in EG and/or EoD
Deadline passed; outcome being checked
- Announced
- 1 Mar 2021
- Due
- 31 Dec 2021
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline data from a randomized, double-blind, placebo-controlled Phase 3 study of lirentelimab in patients with EG and/or EoD expected in the fourth quarter of 2021.”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Topline data from Phase 3 lirentelimab study in EG and/or EoD
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Allakos Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C564824-024909 · Corrections policy